Role of abatacept in the management of rheumatoid arthritis

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1764-1778

  Nogid, Anna ^a,b   Pham, David Q ^a,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

abatacept; CD28; co stimulator; CTLA4 1g; rheumatoid arthritis; T cells

Indexed keywords

ABATACEPT; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ARTHRITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FUNCTIONAL STATUS; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; HYPOTENSION; INFECTION; LOW DRUG DOSE; MEDLINE; MORTALITY; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; PAIN; PHARMACODYNAMICS; PHARYNGITIS; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION;

ANTIGENS, CD; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33845931363     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.020     Document Type: Review

References (35)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46 (2002) 328-346
2. Arthritis prevalence rising as baby boomers grow older (2006). http://www.niams.nih.gov/ne/press/1988/05_05.htm
3. Cooper N.J. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology (Oxford) 39 (2000) 28-33
4. Yelin E., and Wanke L.A. An assessment of the annual and longterm direct costs: The impact of poor function and functional decline. Arthritis Rheum 42 (1999) 1209-1218
5. Doan T., and Massarotti E. Rheumatoid arthritis: An overview of new and emerging therapies. J Clin Pharmacol 45 (2005) 751-762
6. Medical Subject Headings (2006), National Library of Medicine, Bethesda, Md
7. Moreland L.W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebocontrolled clinical trial evaluating CTLA4-Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 (2002) 1470-1479
8. Kremer J.M., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
9. [published correction appears in Arthritis Rheum. 2005;52: 3321 ]. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 2263-2271
10. Study IM101101 (2006). http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005
11. [published correction appears in N Engl J Med. 2005;353:2311]. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necro sis factor alpha inhibition. N Engl J Med 353 (2005) 1114-1123
12. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 144 (2006) 865-876
13. San Diego, Calif. Abstract 1918. Combe B., Weinblatt M., Birbara C., et al. Safety and patient-reported outcomes associated with abatacept in the treatment of rheumatoid arthritis patients who received background disease modifying anti-rheumatic drugs (DMARDS): The ASSURE trial. RA treatment: Biologics and gene therapy I. Poster presented at: 69th Annual Scientific Session of the American College of Rheumatology (November 12-17, 2005)
14. Greene J.L., Leytze G.M., Emswiler J., et al. Covalent dimerization of CD28/ CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem 271 (1996) 26762-26771
15. Peach R.J., Bajorath J., Brady W., et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 180 (1994) 2049-2058
16. [published correction appears in Immunity. 1995;2: following 203]. Linsley P.S., Greene J.L., Brady W., et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1 (1994) 793-801
17. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 (1999) 1243-1252
18. Abstract THU0103. Nadler S., Townsend R., Mikessell G., et al. Abatacept CTLA4Ig; BMS-188667) significantly inhibits T-cell proliferation in viro at clinically relevant concentrations. Ann Rheum Dis 63 Suppl 1 (2004) 142
19. Abstract THU0060. Davis P.M., and Nadler S.J. Abatacept differentially modulates human B celland dendritic cell stimulated T cell effector function. Ann Rheum Dis 64 Suppl 111 (2005) 128
20. San Diego, Calif. Abstract 1164. Buch M., Boyle D., Saleem B., et al. The selective costimulation modulator abatacept decreases synovial in flammation and expression of proinflammatory cytokines in patients with rheumatoid arthritis. T-cells and B-cells: Targets in autoimmunity. Poster presented at: 69th Annual Scientific Session of the American College of Rheumatology (November 12-17, 2005)
21. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
22. Hochberg M.C., Chang R.W., Dwosh I., et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35 (1992) 498-502
23. Fries J.F., Spitz P., Kraines G., and Holman H. Measurement of patient outcome in arthritis. Arth Rheum 23 (1980) 137-145
24. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
25. Felson D.T., Anderson J.J., Boers M., et al., American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
26. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual frame work and item selection. Med Care 30 (1992) 473-483
27. San Diego, Calif. Abstract 1778/557. Westhovens R., Schiff M., Russell A., et al. Abatacept significantly improves health-related quality of life in patients with inadequate responses to anti-TNF therapy: The ATTAIN trial. Epidemiology and health services research III. Poster presented at: 69th Annual Scientific Session of the American College of Rheumatology (November 12-17, 2005)
28. Genant H.K., Jiang Y., Peterfy C., et al. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 41 (1998) 1583-1590
29. Abstract SAT0151. Steinfeld S., Moreland L., Abud C., et al. Rapid and significant improvement in the components of the ACR criteria in abatacept-treated rheumatoid arthritis patients in the phase III AIM (Abatacept in Inadequate responders to Methotrexate) trial. Ann Rheum Dis 64 Suppl 111 (2005) 457
30. Russell A., Kremer J., Irazoque F., et al. Abatacept induces sustained improvements in physical function and reductions in pain over 3 years in rheumatoid arthritis patients with an inadequate response to methotrexate. Ann Rheum Dis 64 Suppl III (2005) 402
31. Abstract FRI0484. Emery P., Russell A., Tate G., et al. Abatacept induces sustained improvements in health-related quality of life, sleep quality and fatigue over 3 years in rheumatoid arthritis patients with inadequate methotrexate responses. Ann Rheum Dis 64 Suppl 111 (2005) 403
32. San Diego, Calif. Abstract 886/188. Moreland L., Kane J., Espinoza L., et al. Safety of abatacept in rheumatoid arthritis patients in five doubleblind, placebo controlled trials. RA treatment: Safety and efficacy of biologics and gene therapy. Poster presented at: 69th Annual Scientific Session of the American College of Rheumatology (November 12-17, 2005)
33. Orencia (abatacept) injection [package insert] (2005), Bristol Myers Squibb Company, Princeton, NJ
34. Study IM101031 (2006). http://www.fda.gov/OHRMS/DOCKETS/ac/05/slides/2005
35. Orencia: Clinical update [Curascript Web site] (2006). http://www.curascript.com/bin.web/documents/Clinical_Update_Orencia.2006.04.03.pdf